Literature DB >> 33689708

Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells.

Yaqiong Li1, Wei Wang1, Aixia Li2, Wei Huang1, Shiman Chen1, Fei Han1, Lingcheng Wang3.   

Abstract

BACKGROUND: Breast cancer is a complex disease. Recent research has examined the anticancer effects of dihydroartemisinin (DHA) on breast cancer. However, the molecular mechanism of the antitumour effect of DHA is unclear.
METHODS: MCF-7 and MDA-MB-231 cell lines were used for in vitro research. BALB/c nude mice were used to establish breast cancer xenografts. The mRNA and protein levels were analysed by qRT-PCR and western blotting, respectively. Flow cytometry was performed to examine cell apoptosis. ELISA kits were used to evaluate the production of interleukin-1β (IL-1β) and IL-18. LDH and ATP release were individually measured with the corresponding kits. A colony formation assay was used to examine the proliferation of breast cancer cells.
RESULTS: DHA inhibited proliferation and induced pyroptosis in breast cancer cells. Mechanistically, DHA activated the expression of absent in melanoma 2 (AIM2), caspase-3 and gasdermin E (DFNA5). In addition, AIM2 promoted DFNA5 expression by activating caspase-3. Knockdown of AIM2 and DFNA5 significantly enhanced breast cancer cell resistance to DHA. In vivo experiments showed that the tumorigenicity of breast cancer cells was significantly suppressed by DHA. Moreover, the AIM2/caspase-3/DFNA5 axis was activated by DHA and then induced pyroptosis.
CONCLUSIONS: Our findings indicate that DHA inhibits tumorigenesis by inducing pyroptosis in breast cancer cells, highlighting a promising therapeutic strategy for breast cancer.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIM2; Breast cancer; DFNA5; Dihydroartemisinin; Pyroptosis

Mesh:

Substances:

Year:  2021        PMID: 33689708     DOI: 10.1016/j.cbi.2021.109434

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  8 in total

Review 1.  Regulated cell death (RCD) in cancer: key pathways and targeted therapies.

Authors:  Fu Peng; Minru Liao; Rui Qin; Shiou Zhu; Cheng Peng; Leilei Fu; Yi Chen; Bo Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.

Authors:  Jianping Zheng; Changhao Liu; Jiandang Shi; Kun Wen; Xiangxin Wang
Journal:  Mol Med Rep       Date:  2021-12-16       Impact factor: 2.952

Review 3.  Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.

Authors:  Xinyu Zhou; Fengzhi Suo; Kristina Haslinger; Wim J Quax
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

Review 4.  Gasdermin E: A Prospective Target for Therapy of Diseases.

Authors:  Xiu-Xiu Liao; Yong-Zhao Dai; Yao-Zhong Zhao; Ke Nie
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

Review 5.  Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer.

Authors:  Liqing Lu; Ye Zhang; Xuemei Tan; Yulia Merkher; Sergey Leonov; Li Zhu; Yalan Deng; Huajun Zhang; Dandan Zhu; Yuying Tan; Ying Fu; Ting Liu; Yongheng Chen
Journal:  Cell Death Discov       Date:  2022-07-27

6.  Genomic analysis quantifies pyroptosis in the immune microenvironment of HBV-related hepatocellular carcinoma.

Authors:  Jiarui Li; Jinghui Yu; Ting Zhang; Xingyu Pu; Yilan Li; Zhongjun Wu
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

7.  BI 2536 induces gasdermin E-dependent pyroptosis in ovarian cancer.

Authors:  Jianting Huo; Yuhong Shen; Yuchen Zhang; Lifei Shen
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

Review 8.  The role of pyroptosis and its crosstalk with immune therapy in breast cancer.

Authors:  Ling Wu; Hongsheng Lu; Yin Pan; Chen Liu; Jinyan Wang; Baofu Chen; Yichao Wang
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.